Downregulation of gelsolin and retinoic acid receptor β expression in gastric cancer tissues through histone deacetylase 1

Journal of Gastroenterology and Hepatology (Australia)

Volumn 19, Issue 2, 2004, Pages 218-224

  Kim, Jin Hyun ^a   Choi, Yang Kyu ^c   Kwon, Ho Jeong ^b   Yang, Han Kwang ^a   Choi, Jae Hoon ^a   Kim, Dae Yong ^a  

^a Seoul National University   (South Korea)

^b Sejong University   (South Korea)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

Gastric cancer; Gelsolin; Histone deacetylase 1; Retinoic acid receptor

Indexed keywords

GELSOLIN; HISTONE DEACETYLASE; MESSENGER RNA; RETINOIC ACID RECEPTOR BETA;

ARTICLE; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CARCINOMA;

EID: 1342310915     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2004.03336.x     Document Type: Article

References (30)

1. Lee DY, Hayes JJ, Pruss D et al. A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell 1993; 72: 73-84.
2. Marks P, Rifkind RA, Richon VM et al. Histone deacetylases and cancer: causes and therapies. Nature Rev. Cancer 2001; 1: 194-202.
3. Turner BM. Histone acetylation and control of gene expression. J. Cell Sci. 1991; 99: 13-20.
4. Yoshida M, Furumai R, Nishiyama M et al. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother. Pharmacol. 2001; 48: 20-6.
5. Patra SK, Patra A, Dahiya R. Histone deacetylase and DNA methyltransferase in human prostate cancer. Biochem. Biophys. Res. Commun. 2001; 287: 705-13.
6. Vigushin DM, Ali S, Pace PE et al. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin. Cancer Res. 2001; 7: 971-6.
7. Choi JH, Kwon HJ, Yoon BI et al. Expression profile of histone deacetylase1 in gastric cancer tissues. Jpn. J. Cancer Res. 2001; 92: 1300-4.
8. Komatsu Y, Tomizaki KY, Tsukamoto M et al. Cyclic hydroxamic-acid- containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. Cancer Res. 2001; 61: 4459-66.
9. Saito A, Yamashita T, Mariko Y et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl Acad. Sci. USA 1999; 96: 4592-7.
10. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 1990; 265: 17174-9.
11. Han JW, Ahn SH, Park SH et al. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res., 2000; 60: 6068-74.
12. Kim YB, Ki SW, Yoshida M, Horinouchi S. Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells. J. Antibiot. 2000; 53: 1191-200.
13. Demary K, Wong L, Spanjaard RA. Effects of retinoic acid and sodium butyrate on gene expression, histone acetylation and inhibition of proliferation of melanoma. Cancer Lett. 2001; 163: 103-7.
14. Saverio M, Valerie H, Nisan B et al. A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells. Proc. Natl Acad. Sci. USA 1997; 94: 11295-300.
15. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997; 389: 349-52.
16. Suzuki T, Yokozaki H, Kuniyasu H et al. Effect of trichostatin A on cell growth and expression of cell cycle- and apoptosis-related molecules in human gastric and oral carcinoma cell lines. Int. J. Cancer 2000; 88: 992-7.
17. Yin HL. Gelsolin: calcium- and polyphosphoinositide-regulated actin-modulating protein. Bioessays 1987; 7: 176-9.
18. Kwiatkowski DJ. Functions of gelsolin: motility, signaling, apoptosis, cancer. Curr. Opin. Cell Biol. 1999; 11: 103-8.
19. Kuzumaki N, Tanaka M, Sakai N, Fujita H. [Tumor suppressive function of gelsolin.] Gan To Kagaku Ryoho, 1997; 24: 1436-41. (In Japanese.)
20. Tanaka M, Müllauer L, Ogiso Y et al. Gelsolin: a candidate for suppressor of human bladder cancer. Cancer Res. 1995; 55: 3228-32.
21. Prasad SC, Thraves PJ, Dritschilo A, Kuettel MR. Protein expression changes associated with radiation-induced neoplastic progression of human prostate epithelial cells. Electrophoresis 1999; 20: 1065-74.
22. Dong Y, Asch HL, Medina D et al. Concurrent deregulation of gelsolin and cyclin D1 in the majority of human and rodent breast cancers. Int. J. Cancer 1999; 81: 930-8.
23. Mielnicki LM, Ying AM, Head KL, Asch HL, Asch BB. Epigenetic regulation of gelsolin expression in human breast cancer cells. Exp. Cell Res. 1999; 249: 161-76.
24. Chambon P, A. decade of molecular biology of retinoic acid receptors. FASEB J. 1996; 10: 940-54.
25. Sirchia SM, Ferguson AT, Sironi E et al. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells. Oncogene 2000; 19: 1556-63.
26. Blanco JC, Minucci S, Lu J et al. The histone acetylase PCAF is a nuclear receptor coactivator. Genes Dev. 1998; 12: 1638-51.
27. Gerbert JF, Moghal N, Frangioni JV et al. High frequency of retinoic acid receptor β abnormalities in human lung cancer. Oncogene 1991; 6: 1859-68.
28. Lotan R, Xu C, Lippman SM et al. Suppression of retinoic acid receptor β in premalignant oral lesions and its upregulation by isotretinoin. N. Engl. J. Med. 1995; 332: 1405-10.
29. Seewaldt VL, Johnson BS, Parker MB et al. Expression of retinoic acid receptor-β mediates retinoic acid-induced growth arrest and apoptosis in breast cancer cells. Cell Growth Differ. 1995; 6: 1077-88.
30. Zhang W, Rashid A, Wu H, Xu XC. Differential expression of retinoic acid receptor and p53 protein in normal, premalignant, and malignant esophageal tissues. J. Cancer Res. Clin. Oncol. 2001; 127: 237-42.